SWOG JBR10:STUDY OF ADJUVANT CHEMOTHERAPY, VINORELBINE & CISPLATIN, L

SWOG JBR10：辅助化疗长春瑞滨的研究

• 批准号: 6265784
• 负责人: ALAN MARSHALL MILLER
• 金额: $ 1.12万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-07-19 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265784
• 关键词: antineoplastics; cis platinum compound; clinical research; drug screening /evaluation; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; nonsmall cell lung cancer

Non-small cell lung cancer (NSCLC) constitutes the principal cause of cancer death for both men and women in North America. Despite vigorous efforts at curbing tobacco consumption, the incidence of lung cancer has yet to show a substantial overall decline and in fact is increasing in some groups, particularly women. As a result, novel therapeutic strategies aimed at improving survival and cure rates are needed. This is a multicenter, nonblinded randomized cooperative group trial to compare whether 2 drugs cisplatin and vinorelbine given adjuvantly will significantly impact disease-free survival and overall survival. Patients eligible for this study must have histological evidence of a non-small cell primary cancer of the lung that has been completely resected and fulfills the required staging criteria.

非小细胞肺癌（NSCLC）是北美男性和女性癌症死亡的主要原因。 尽管为限制烟草消费作出了积极努力，但肺癌发病率尚未显示出整体大幅下降，事实上在某些群体中，特别是妇女中，肺癌发病率正在上升。 因此，需要旨在提高生存率和治愈率的新的治疗策略。 这是一项多中心、非盲、随机、协作组试验，旨在比较顺铂和长春瑞滨两种药物联合使用是否会显著影响无病生存期和总生存期。 有资格参加本研究的患者必须有非小细胞原发性肺癌的组织学证据，并且已经完全切除并符合所需的分期标准。